Stay updated on Durvalumab & Tremelumab vs SoC in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Durvalumab & Tremelumab vs SoC in NSCLC Clinical Trial page.

Latest updates to the Durvalumab & Tremelumab vs SoC in NSCLC Clinical Trial page
- Check7 days agoChange DetectedIn the version history, 2026-02-12 adds Contacts/Locations and Study Status, and 2026-01-26 adds the entry 54; a deletion occurred on 2025-09-16.SummaryDifference0.3%

- Check14 days agoChange DetectedA new version entry 'Revision: v3.4.2' was added to the version history, and notices including a government funding lapse message and 'Revision: v3.4.1' were removed. These changes are administrative and do not alter core page content or study data. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check21 days agoChange DetectedA site-wide notice about a lapse in government funding and NIH operating status was added, and the revision label updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check28 days agoChange DetectedThe history page now includes a glossary, green highlights for additions, red highlights for deletions, and explicit revision labels (e.g., v3.4.0). These updates affect presentation only and do not change the study data. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check42 days agoChange DetectedRevision: v3.3.4 was added to the Record History and Revision: v3.3.3 was removed.SummaryDifference0.1%

- Check63 days agoChange DetectedFooter updates include changing the revision label from v3.3.2 to v3.3.3 and removing the HHS Vulnerability Disclosure link. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Durvalumab & Tremelumab vs SoC in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab & Tremelumab vs SoC in NSCLC Clinical Trial page.